Agnieszka Wozniak

Author PubWeight™ 36.57‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema. Am J Pathol 2009 1.92
2 Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients. Hum Mol Genet 2006 1.68
3 Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors. Lab Invest 2007 1.56
4 Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. Mod Pathol 2008 1.20
5 Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation. Clin Cancer Res 2008 1.16
6 Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas. J Clin Oncol 2013 1.14
7 Mitotic checkpoints and chromosome instability are strong predictors of clinical outcome in gastrointestinal stromal tumors. Clin Cancer Res 2011 1.14
8 A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal. Clin Cancer Res 2012 1.05
9 Clinical utility of the new American Joint Committee on Cancer staging system for gastrointestinal stromal tumors: current overall survival after primary tumor resection. Cancer 2011 1.05
10 High efficacy of panobinostat towards human gastrointestinal stromal tumors in a xenograft mouse model. Clin Cancer Res 2009 1.02
11 Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma. Expert Opin Pharmacother 2008 1.02
12 Advances in molecular characterization and targeted therapy in dermatofibrosarcoma protuberans. Sarcoma 2011 1.01
13 Coactivated platelet-derived growth factor receptor {alpha} and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma. Cancer Res 2010 0.98
14 KIT overexpression and amplification in gastrointestinal stromal tumors (GISTs). Biochim Biophys Acta 2005 0.95
15 The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations. Clin Cancer Res 2011 0.93
16 The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models. Mol Cancer Ther 2012 0.92
17 The heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumors. Mol Cancer Ther 2011 0.92
18 Frequent activation of EGFR in advanced chordomas. Clin Sarcoma Res 2011 0.92
19 Soft tissue sarcoma: an update on systemic treatment options for patients with advanced disease. Oncol Res Treat 2014 0.92
20 The DREAM complex mediates GIST cell quiescence and is a novel therapeutic target to enhance imatinib-induced apoptosis. Cancer Res 2013 0.91
21 Efficiency of the Cepheid Xpert vanA/vanB assay for screening of colonization with vancomycin-resistant enterococci during hospital outbreak. Antonie Van Leeuwenhoek 2011 0.90
22 Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma. Future Oncol 2007 0.89
23 Rearrangement of the COL12A1 and COL4A5 genes in subungual exostosis: molecular cytogenetic delineation of the tumor-specific translocation t(X;6)(q13-14;q22). Int J Cancer 2006 0.86
24 Malignant ectomesenchymoma: genetic profile reflects rhabdomyosarcomatous differentiation. Diagn Mol Pathol 2007 0.85
25 A girl with duplication 9q34 syndrome. Am J Med Genet A 2007 0.84
26 Expression and significance of HER family receptors in neuroblastic tumors. Clin Exp Metastasis 2011 0.84
27 Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors. Med Sci Monit 2007 0.83
28 Clinical presentation, pathological features and natural course of metastatic uveal melanoma, an orphan and commonly fatal disease. Oncology 2014 0.82
29 Loss of heterozygosity at chromosomes 3p and 17p in primary non-small cell lung cancer. Anticancer Res 2005 0.82
30 Identification of a novel, recurrent MBTD1-CXorf67 fusion in low-grade endometrial stromal sarcoma. Int J Cancer 2013 0.82
31 Changes in expression of serine proteases HtrA1 and HtrA2 during estrogen-induced oxidative stress and nephrocarcinogenesis in male Syrian hamster. Acta Biochim Pol 2008 0.81
32 Loss of heterozygosity on chromosome 22q in gastrointestinal stromal tumors (GISTs): a study on 50 cases. Lab Invest 2005 0.80
33 EGFR, PIK3CA and PTEN gene status and their protein product expression in neuroblastic tumours. Folia Neuropathol 2010 0.79
34 A unique occurrence of a cerebral atypical teratoid/rhabdoid tumor in an infant and a spinal canal primitive neuroectodermal tumor in her father. J Neurooncol 2003 0.79
35 Prognostic significance of HER2 expression in neuroblastic tumors. Mod Pathol 2010 0.79
36 Unbiased compound screening identifies unexpected drug sensitivities and novel treatment options for gastrointestinal stromal tumors. Cancer Res 2014 0.78
37 Promoting role of cholecystokinin 2 receptor (CCK2R) in gastrointestinal stromal tumour pathogenesis. J Pathol 2012 0.78
38 Periventricular heterotopia in a boy with interstitial deletion of chromosome 4p. Eur J Med Genet 2007 0.77
39 Influence of non-optimal levels of electrical stimulation in cochlear implantees on hearing benefits. Cochlear Implants Int 2010 0.75
40 Primary intrathoracic biphasic synovial sarcoma--a case report. Pol J Pathol 2005 0.75
41 A computer-based, word-free phoneme identification test Teetahtoo--adaptation into Polish. Cochlear Implants Int 2010 0.75
42 Nutritional assessment in Polish men with cardiovascular diseases. Rocz Panstw Zakl Hig 2013 0.75
43 Retroperitoneal dedifferentiated liposarcomas with production of β-human chorionic gonadotropin--a distinct sarcoma entity? Onkologie 2011 0.75
44 Overcoming Cost Implications of Mutational Analysis in Patients with Gastrointestinal Stromal Tumors: A Pragmatic Approach. Oncol Res Treat 2016 0.75